UNSPSC 51373323: Aspirin/caffeine/hydrocodone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373323 Aspirin/caffeine/hydrocodone (Commodity) does not align with the actual work state and local governments are buying under this code. Recent state and local solicitations tagged with this code are procuring naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer pharmacy benefit programs — none of which match the specific opioid-caffeine combination the code nominally describes. The mismatch suggests that state and local procurement offices are using this code as a catch-all category for pharmaceutical procurement rather than for the narrowly defined product line the code's name implies. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances managing benefits for state and local government facilities.

Recent activity appears concentrated in Florida and Texas, with multi-state reach through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) covering participating jurisdictions including Oregon. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas Health and Human Services Commission issued a Request for Information (HHS0017013) on April 3, 2026, to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (Solicitation Number S1070000015802) posted January 20, 2026, with responses due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to state and local government facilities across multiple states.